Brad Hessel is an investment advisor registered with the state of North Carolina (USA). With a background in history and simulation design, he worked in information services for First Boston and Credit Suisse in the 80s and 90s and ultimately moved into the knowledge management field. He has managed funds for family and friends informally for thirty years. In 2003, he took on a knowledge management client who was planning to start a macro-based hedge fund. Work in support of that client demonstrated the potential of using a macro-based investment strategy both to produce a superior return on investment and to explain to clients the effects of macro trends on their lives, apart from their 401K balances. In 2006, Brad passed the Series 6 exam and registered as an investment advisor in the State of North Carolina. The Intelledgement Macro Strategy Investment Portfolio (IMSIP) was initiated 31 December 2006: http://caps.fool.com/player/intelledgement.aspx
Certified Financial Planner Professional with Teak Tree Capital Management, LLC, an independent RIA in Fort Worth, TX. Advisor with Sudden Money Institute, a professional research collaboration with a systematic process for assisting people and families who have had life-changing financial events. The process is under continuous development and encorporates individual psychology and family/social dynamics.
My growing edge is how individuals and families successfully adapt to a sudden increase in their wealth.
Prior to entering the financial services field in 1999 I was a Clinical Social Worker providing individual and family therapy for 25 years. During that time I confused a bull market with skill. I have been humbled in the 21st Century.
Andrew McDonald is a healthcare investment professional with expertise in identifying transformative medicines as well as in forecasting clinical trial, regulatory, and sales outcomes. Prior to co-founding LifeSci Advisors, Andrew most recently served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Co-head of Healthcare Research and Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer from 2000-2001. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
Brian Marckx, CFA is the Senior Medical Device / Diagnostics Analyst with Zacks Investment Research. I cover small and micro-cap medical device and diagnostic companies. Focus is development-stage companies with novel and emerging technologies as well as already established names still flying under the radar.
Prior to joining Zacks, Brian worked as a high-yield bond analyst on Wachovia Securities’ institutional trading desks where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Brian has covered the medical device, pharmaceutical and biotechnology industries since joining Zacks.
Brian has been quoted in numerous publications including The Wall Street Journal, Barron's, Bloomberg-Businessweek and Kiplinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. Brian graduated with a B.S. in Finance from St. John Fisher College and received his MBA from Wake Forest University. Brian is also a Chartered Financial Analyst charterholder.
I am a value investor to the greatest extent possible. I also favor dividend stocks. I try to be a buy-and-hold investor, but sometimes I can't avoid the tempation to ring the register or to accumulate the inevitable tax loss. The main thing I have learned is that I have lost more money by selling too soon than for any other reason. I reside in Henderson, NV.
James Hill is a clinical assistant professor of radiology at the University of Southern California Medical School, and a patent lawyer and partner at McDermott Will & Emery.
Although he relies on publicly available information and makes reasonable efforts to confirm its accuracy, all comments made in his blog posts and articles should be considered only opinion.
Nothing in these posts or articles constitutes legal, medical, or investment advice. Always do your own due diligence and confirm all information yourself.
I am a day trader at one of the biggest prop firms in New York. I trade equities and equity options but closely follow all asset classes. I have over 5 years of trading/investing experience and am an unabashed, cynical contrarian. I have a major interest in biotechnology and believe now is a perfect time to be buying as the industry has been largely forgotten/loathed since the 2000 bubble and over the next 10-20 years it will produce the greatest returns in stock market history